Compare CELC & LAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CELC | LAZ |
|---|---|---|
| Founded | 2011 | 1848 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.4B |
| IPO Year | 2017 | 2004 |
| Metric | CELC | LAZ |
|---|---|---|
| Price | $53.29 | $35.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 10 |
| Target Price | ★ $150.85 | $43.38 |
| AVG Volume (30 Days) | 920.9K | ★ 1.4M |
| Earning Date | 11-05-2026 | 10-22-2026 |
| Dividend Yield | N/A | ★ 5.32% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.20 |
| Revenue | N/A | ★ $3,186,466,000.00 |
| Revenue This Year | N/A | $5.98 |
| Revenue Next Year | $1,921.71 | $19.40 |
| P/E Ratio | ★ N/A | $31.33 |
| Revenue Growth | N/A | ★ 1.48 |
| 52 Week Low | $53.54 | $34.13 |
| 52 Week High | $151.02 | $58.75 |
| Indicator | CELC | LAZ |
|---|---|---|
| Relative Strength Index (RSI) | 30.06 | 38.25 |
| Support Level | N/A | $34.65 |
| Resistance Level | $72.76 | $37.58 |
| Average True Range (ATR) | 4.24 | 1.68 |
| MACD | -1.03 | -0.39 |
| Stochastic Oscillator | 0.16 | 0.14 |
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Lazard Inc is a financial advisory and asset management firm with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Geographically, the company earns key revenue in the Americas, EMEA then Asia-Pacific.